MARKET

GKOS

GKOS

Glaukos Corp
NYSE
103.18
-4.57
-4.24%
Closed 16:34 03/27 EDT
OPEN
106.74
PREV CLOSE
107.75
HIGH
106.74
LOW
102.12
VOLUME
625.33K
TURNOVER
0
52 WEEK HIGH
130.23
52 WEEK LOW
73.16
MARKET CAP
5.99B
P/E (TTM)
-31.4391
1D
5D
1M
3M
1Y
5Y
1D
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For Keratoconus - What's Changed
Simply Wall St · 3d ago
Seaport Research med technology analyst holds analyst/industry conference call
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), Aveanna Healthcare Holdings (AVAH) and Glaukos (GKOS)
TipRanks · 6d ago
Weekly Report: what happened at GKOS last week (0316-0320)?
Weekly Report · 6d ago
Stifel Nicolaus Sticks to Its Buy Rating for Glaukos (GKOS)
TipRanks · 03/20 13:17
How Investors May Respond To Glaukos (GKOS) Incision‑Free Epioxa Keratoconus Therapy Launch And Access Push
Simply Wall St · 03/19 13:08
Glaukos announces commercial availability of Epioxa HD/Epioxa
TipRanks · 03/19 11:12
Weekly Report: what happened at GKOS last week (0309-0313)?
Weekly Report · 03/16 10:04
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.